ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy

Keystone Symposia: Cancer Stem Cells, 2021

« The Neuropilin-2 Targeting Antibody ATYR2810 Inhibits Non-Small Cell Lung Cancer Tumor Growth in Monotherapy and Combination Therapy

Engineering an Anti-Neuropilin-2 (NRP2) Antibody that Selectively Blocks NRP2 Interactions with Semaphorin and Plexin »

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy